Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $99.00 at Wedbush

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price upped by stock analysts at Wedbush from $72.00 to $99.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 23.68% from the stock’s current price.

KNSA has been the subject of a number of other research reports. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Finally, Canaccord Genuity Group increased their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $77.57.

Kiniksa Pharmaceuticals International Trading Up 0.8%

Shares of NASDAQ KNSA traded up $0.60 during midday trading on Wednesday, reaching $80.05. The company had a trading volume of 781,789 shares, compared to its average volume of 729,008. The business’s 50-day simple moving average is $57.59 and its 200 day simple moving average is $50.44. The stock has a market cap of $6.16 billion, a P/E ratio of 88.75 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 1 year low of $29.66 and a 1 year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Analysts predict that Kiniksa Pharmaceuticals International will post 1.25 earnings per share for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the transaction, the chief executive officer owned 48,565 shares in the company, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider directly owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. This trade represents a 47.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 109,130 shares of company stock worth $5,877,070 over the last ninety days. 51.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. KBC Group NV purchased a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $34,000. Smartleaf Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $36,000. EverSource Wealth Advisors LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Citigroup raised its price target to $100 from $60 and upgraded KNSA to “buy.” The new target implies approximately 25% upside from the recently reported share price, signaling increased confidence in Kiniksa’s growth outlook. Benzinga
• Positive Sentiment: Second-quarter revenue significantly exceeded expectations. Kiniksa reported revenue of $243.6 million versus the $226.5 million consensus estimate, driven by ARCALYST net product revenue growth of approximately 55% year over year. Kiniksa Second-Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 ARCALYST revenue outlook to $980 million-$995 million, well above the roughly $940.1 million analyst consensus. The higher guidance supports expectations for continued commercial momentum. Kiniksa Q2 2026 Guidance Announcement
• Positive Sentiment: KPL-387 produced rapid and sustained reductions in pain and inflammation in Phase 2 testing. Kiniksa selected the 300 mg monthly dose for Phase 3, and its pivotal recurrent-pericarditis trial is now enrolling and dosing patients, creating an additional potential growth driver. KPL-387 Portfolio Update
• Neutral Sentiment: Adjusted quarterly earnings were $0.30 per share, matching consensus but improving from $0.23 per share a year earlier. The earnings result itself was supportive, though the revenue beat and raised guidance were the stronger catalysts. Zacks KNSA Earnings Report

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.